Data gathered: March 6
AI Stock Analysis - Cardiff Oncology (CRDF)
Analysis generated May 8, 2024. Powered by Chat GPT.
Cardiff Oncology is a biotechnology firm focused on developing new treatments for cancer patients with unmet medical needs. The company's strategy involves leveraging its expertise in oncology to advance targeted therapies, aiming to combat cancer more effectively. Given the challenging and competitive nature of the biotech industry, Cardiff Oncology's approach emphasizes innovation and precision medicine.
Stock Alerts - Cardiff Oncology (CRDF)
 |
Cardiff Oncology | March 5 Price is up by 6% in the last 24h. |
|
Cardiff Oncology | March 3 Price is down by -5.9% in the last 24h. |
|
Cardiff Oncology | February 28 Price is up by 6.7% in the last 24h. |
|
Cardiff Oncology | February 27 Price is down by -5.2% in the last 24h. |
Alternative Data for Cardiff Oncology
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Google Trends | 5 | Sign up | Sign up | Sign up |
| Patents | 6 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 3 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,176 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,571 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,060 | Sign up | Sign up | Sign up |
| Twitter Mentions | 14 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 55 | Sign up | Sign up | Sign up |
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California.
| Price | $4.27 |
| Target Price | Sign up |
| Volume | 1,280,000 |
| Market Cap | $248M |
| Year Range | $2.05 - $5.35 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Contrasting Immatics (NASDAQ:IMTX) & Cardiff Oncology (NASDAQ:CRDF)March 4 - ETF Daily News |
 |
Critical Survey: Kymera Therapeutics (NASDAQ:KYMR) and Cardiff Oncology (NASDAQ:CRDF)March 4 - ETF Daily News |
|
Equities Analysts Issue Forecasts for CRDF Q1 EarningsMarch 4 - ETF Daily News |
 |
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call TranscriptFebruary 27 - SeekingAlpha |
 |
Financial Contrast: Cardiff Oncology (NASDAQ:CRDF) versus Vir Biotechnology (NASDAQ:VIR)February 24 - ETF Daily News |
Cardiff Oncology to Present at Upcoming Investor ConferencesFebruary 24 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 170,000 | 3.1M | -3M | -12M | -13M | -0.250 |
| Q2 '24 | 160,000 | 3.2M | -3.1M | -12M | -12M | -0.260 |
| Q1 '24 | 1.1M | 3.1M | -2M | -10M | -11M | -0.220 |
| Q4 '23 | 160,000 | 2.7M | -5.6M | -9.3M | -10M | -0.210 |
| Q3 '23 | 1.2M | 2.9M | -1.7M | -9.7M | -11M | -0.220 |
Insider Transactions View All
| Levine James E. filed to buy 67,716 shares at $5. December 18 '24 |
| Levine James E. filed to buy 65,316 shares at $5.4. December 18 '24 |
| Levine James E. filed to buy 62,564 shares at $3.8. December 18 '24 |
| TANNENBAUM RENEE P filed to buy 20,000 shares at $3.4. December 16 '24 |
| PACE GARY W filed to buy 1,059,376 shares at $2.6. December 12 '24 |
Similar companies
Read more about Cardiff Oncology (CRDF) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Cardiff Oncology?
The Market Cap of Cardiff Oncology is $248M.
What is the current stock price of Cardiff Oncology?
Currently, the price of one share of Cardiff Oncology stock is $4.27.
How can I analyze the CRDF stock price chart for investment decisions?
The CRDF stock price chart above provides a comprehensive visual representation of Cardiff Oncology's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cardiff Oncology shares. Our platform offers an up-to-date CRDF stock price chart, along with technical data analysis and alternative data insights.
Does CRDF offer dividends to its shareholders?
As of our latest update, Cardiff Oncology (CRDF) does not offer dividends to its shareholders. Investors interested in Cardiff Oncology should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Cardiff Oncology?
Some of the similar stocks of Cardiff Oncology are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.